News - Reven Pharmaceuticals Recent Reven Pharma press releases and other news in the pharma industry, including broad medical treatment news and current issues
Reven Pharmaceuticals Response - Reven hits back, opposing SEC’s . . . In early 2020, the COVID-19 pandemic disrupted many of Reven’s plans, yet Reven continued to make progress toward its goals, including by engaging Jeff Halverson as its CFO and tasking him with helping complete tax returns for Reven and its related entities in preparation for an audit
Overview - Reven Pharmaceuticals Reven is dedicated to investigating neglected diseases with unmet therapeutic needs and areas of medicine where current standard of care is often not successful Our goal is to deliver innovative medicines based on the RJX technology to patients in need
REVEN ANNOUNCES A STRATEGIC LICENSING PARTNERSHIP WITH ENLIGHTENED . . . reven announces a strategic licensing partnership with enlightened nutraceutical solutions, llc (ens) to allow ens to leverage reven’s clinical research in anti-inflammatory and antioxidant medicine toward its efforts to develop new proprietory vitamin and nutrient based products
Reven Announces New Chief Operating Officer Reven is pleased to announce the appointment of Daniel Hoffman as Chief Operating Officer, effective immediately Mr Hoffman will support co-founders Peter Lange, Michael Volk, and Brian Denomme in executing their vision in bringing the company's flagship platform drug Rejuveinix (RJX) to market
Social Accountability - Reven Pharmaceuticals At Reven, we believe that good medicine strives to serve ALL patients with better outcomes and affordable solutions Our vision is to reduce patient cost by striving to deliver definitive outcomes with multi-modal treatments, instead of single-mode therapies that only delay disease progression
Reven’s Co-Founder Michael Volk Appears on Cheddar News The published data from these clinical and non-clinical studies provided the medical-scientific rationale for Reven’s clinical development strategy for RJX and a clinical study in COVID-19 patients